Chinese Pharmaceutical R&D Takes A Great Leap Forward With FDA Approved Clinical Trials In The U.S.

SHANGHAI - The U.S. Food and Drug Administration has given the green light for Jiangsu Hengrui Medicine to conduct Phase I clinical trials on an innovative diabetes drug in the U.S. This is the first time FDA has approved an application to stage a clinical trial of a China-discovered, synthesized drug